HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome

Creative Commons License

Files in This Item:
Yokota_et_al-2017-Journal_of_Diabetes_Investigation.pdf365.06 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/67069

Title: Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome
Authors: Yokota, Takashi Browse this author →KAKEN DB
Kinugawa, Shintaro Browse this author →KAKEN DB
Hirabayashi, Kagami Browse this author
Suga, Tadashi Browse this author →KAKEN DB
Takada, Shingo Browse this author →KAKEN DB
Omokawa, Masashi Browse this author
Kadoguchi, Tomoyasu Browse this author
Takahashi, Masashige Browse this author
Fukushima, Arata Browse this author →KAKEN DB
Matsushima, Shouji Browse this author
Yamato, Mayumi Browse this author →KAKEN DB
Okita, Koichi Browse this author →KAKEN DB
Tsutsui, Hiroyuki Browse this author →KAKEN DB
Keywords: Clinical
Metabolic syndrome
Treatment drug
Issue Date: Jul-2017
Publisher: John Wiley & Sons
Journal Title: Journal of Diabetes Investigation
Volume: 8
Issue: 4
Start Page: 535
End Page: 541
Publisher DOI: 10.1111/jdi.12606
Abstract: Aims/Introduction: Low aerobic capacity is a strong and independent predictor of all-cause mortality in patients with metabolic syndrome (MetS). Here, we investigated the effects of pioglitazone treatment on whole-body aerobic capacity and skeletal muscle energy metabolism in MetS patients. Materials and Methods: A total of 14 male patients with MetS received oral pioglitazone 15 mg/day for 4 months. To assess whole-body aerobic capacity, exercise testing with a bicycle ergometer was carried out before and after pioglitazone treatment. To assess skeletal muscle energy metabolism, intramyocellular lipid in the resting leg and high-energy phosphates in the calf muscle during plantar-flexion exercise were measured using 1proton- and 31phosphorus magnetic resonance spectroscopy, respectively. Results: Pioglitazone significantly increased peak oxygen uptake (25.1 ± 4.9 mL/kg/min pretreatment vs 27.2 ± 3.9 mL/kg/min post- treatment, P < 0.05) and anaerobic threshold (12.7 ± 1.9 mL/kg/min pretreatment vs 13.6 ± 1.6 mL/kg/min post-treatment, P < 0.05), although daily physical activity was comparable before and after the treatment. Intramyocellular lipid content was significantly reduced after pioglitazone treatment by 26%, indicating improved skeletal muscle fatty acid metabolism. Pioglitazone also significantly decreased the muscle phosphocreatine loss during exercise by 13%, indicating improved skeletal muscle high-energy phosphate metabolism. Notably, the increase in anaerobic threshold; that is, submaximal aerobic capacity, closely correlated with the decrease in intramyocellular lipid content after pioglitazone treatment. Conclusions: Pioglitazone significantly improved the MetS patients' whole-body aerobic capacity and skeletal muscle energy metabolism. The beneficial effect of pioglitazone on whole-body aerobic capacity might be at least in part through improved fatty acid metabolism in the skeletal muscle.
Rights: https://creativecommons.org/licenses/by-nc/4.0/
Type: article
URI: http://hdl.handle.net/2115/67069
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 絹川 真太郎

Export metadata:

OAI-PMH ( junii2 , jpcoar )


 

Feedback - Hokkaido University